Análise opcional do produto
Com a sua autorização, usamos análises limitadas e respeitadoras da privacidade para perceber que percursos de investigação funcionam. Não usamos rastreadores publicitários nem gravação de sessões. Pode alterar esta escolha nas Preferências. Leia a Política de Privacidade.
Thermo Fisher Scientific Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $240.9B | |
|---|---|---|
| P/E (forward) | 23.7x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $39.21B | $44.92B | $42.86B | $42.88B | $44.56B | +3.2% |
| Gross profit | $19.63B | $19.01B | $17.56B | $17.73B | $16.78B | -3.9% |
| Operating income | $10.03B | $8.39B | $6.86B | $7.34B | $7.75B | -6.3% |
| Net income | $7.73B | $6.95B | $6.00B | $6.34B | $6.70B | -3.5% |
| EPS (diluted) | $19.46 | $17.63 | $15.45 | $16.53 | $17.74 | -2.3% |
| EBITDA | $11.97B | $11.94B | $6.86B | $11.80B | $11.47B | -1.1% |
| R&D | $1.41B | $1.47B | $1.34B | $1.39B | $1.40B | -0.2% |
| SG&A | $8.01B | $8.99B | $8.45B | $8.60B | $8.73B | +2.2% |
Recent company headlines from major financial publishers.
The Base case represents our modal expectation where Thermo Fisher delivers steady operational execution in line with management guidance. Laboratory Products and Biopharma Services maintains steady recurring demand, while Analytical Instruments sustains moderate single-digit expansion. This path yields our Fair value of $318.21 (implied return of -51.5% at 60.0% probability) versus $656.45 as of $656.45 (as of 2026-09-21). Disconfirmation would appear if customer biopharma spending decelerates below guided ranges or tariff friction erodes gross margin.
In the Bull case, bioprocessing order velocity accelerates swiftly, proprietary analytical instrumentation captures greater market share across Asian and European clinical laboratories, and academic spending rebounds robustly. Under these conditions, valuation expands toward $393.17 representing an expected return of -40.1% at a modeled probability of 20.0%. Confirmation requires consecutive quarters of organic revenue expansion exceeding upper guidance bands and operating margin expansion in analytical tools.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 6.7% | $373 | $392 | $417 | $449 | $491 |
| 7.7% | $330 | $343 | $358 | $377 | $401 |
| 8.7% | $299 | $308 | $318 | $330 | $345 |
| 9.7% | $275 | $281 | $288 | $297 | $307 |
| 10.7% | $255 | $260 | $265 | $271 | $278 |
Upcoming earnings date and setup when available.
A classificação que a edição de pesquisa publicada em cada mês trazia. Uma classificação compara o preço na data da análise com o valor justo; não é um registro de se a avaliação se confirmou.
| Ano | jan. | fev. | mar. | abr. | mai. | jun. | jul. | ago. | set. | out. | nov. | dez. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
